Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Protoc ; 3(4): e746, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37098732

ABSTRACT

Protein posttranslational modification (PTM) is a biochemical mechanism benefitting cellular adaptation to dynamic intracellular and environmental conditions. Recently, several acylation marks have been identified as new protein PTMs occurring on specific lysine residues in mammalian cells: isobutyrylation, methacrylation, benzoylation, isonicotinylation, and lactylation. These acylation marks were initially discovered to occur on nucleosomal histones, but they potentially occur as prevalent biomarkers on non-histone proteins as well. The existence of these PTMs is a downstream consequence of metabolism and demonstrates the intimate crosstalk between active cellular metabolites and regulation of protein function. Emerging evidence indicates that these acylation marks on histones affect DNA transcription and are functionally distinct from the well-studied lysine acetylation. Herein, we discuss enzymatic regulation and metabolic etiology of these acylations, 'reader' proteins that recognize different acylations, and their possible physiological and pathological functions. Several of these modifications correlate with other well-studied acylations and fine-tune the regulation of gene expression. Overall, findings of these acylation marks reveal new molecular links between metabolism and epigenetics and open up many questions for future investigation. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC.


Subject(s)
Histones , Lysine , Animals , Histones/genetics , Histones/chemistry , Histones/metabolism , Lysine/chemistry , Lysine/metabolism , Epigenesis, Genetic , Acylation , Biomarkers/metabolism , Mammals/metabolism
2.
FASEB J ; 37(3): e22820, 2023 03.
Article in English | MEDLINE | ID: mdl-36801982

ABSTRACT

Epidemiological studies suggest that fetal growth restriction (FGR) caused by gestational cholestasis is associated with elevated serum cholic acid (CA). Here, we explore the mechanism by which CA induces FGR. Pregnant mice except controls were orally administered with CA daily from gestational day 13 (GD13) to GD17. Results found that CA exposure decreased fetal weight and crown-rump length, and increased the incidence of FGR in a dose-dependent manner. Furthermore, CA caused placental glucocorticoid (GC) barrier dysfunction via down-regulating the protein but not the mRNA level of placental 11ß-Hydroxysteroid dehydrogenase-2 (11ß-HSD2). Additionally, CA activated placental GCN2/eIF2α pathway. GCN2iB, an inhibitor of GCN2, significantly inhibited CA-induced down-regulation of 11ß-HSD2 protein. We further found that CA caused excessive reactive oxygen species (ROS) production and oxidative stress in mouse placentas and human trophoblasts. NAC significantly rescued CA-induced placental barrier dysfunction by inhibiting activation of GCN2/eIF2α pathway and subsequent down-regulation of 11ß-HSD2 protein in placental trophoblasts. Importantly, NAC rescued CA-induced FGR in mice. Overall, our results suggest that CA exposure during late pregnancy induces placental GC barrier dysfunction and subsequent FGR may be via ROS-mediated placental GCN2/eIF2α activation. This study provides valuable insight for understanding the mechanism of cholestasis-induced placental dysfunction and subsequent FGR.


Subject(s)
Placenta Diseases , Placenta , Pregnancy , Female , Mice , Humans , Animals , Placenta/metabolism , Reactive Oxygen Species/metabolism , 11-beta-Hydroxysteroid Dehydrogenase Type 2/genetics , Fetal Growth Retardation/chemically induced , Eukaryotic Initiation Factor-2/metabolism , Placenta Diseases/metabolism
3.
Vet Microbiol ; 257: 109076, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33957572

ABSTRACT

The Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne hemorrhagic zoonotic disease, which is potentially fatal in human with mortality rates ranging from 16.2%-32%. The rabies virus (RABV) LBNSE vector expressing foreign antigens have shown considerable promise as vaccines against viral diseases, which is effective and safe. In the present study, we generated a recombinant RABV rLBNSE-Gn expressing a SFTSV glycoprotein Gn by reverse genetic technology to control rabies and SFTS in animals. An extra insertion of Gn gene did not impact replication of the recombinant virus rLBNSE-Gn in NA and BHK-21 cells compared to the parent rLBNSE strain. The SFTSV Gn gene together with RABV N and G genes were efficiently expressed in rLBNSE-infected Vero cells by immunostaining and immune blots. A single dose of 107 FFU of the rLBNSE-Gn intramuscularly inoculated in BALB/c mice induced rapid and robust humoral responses against both RABV and SFTSV without any signs of disease or weight loss. Compared to the rLBNSE and DMEM groups, the extra Gn expression contributed to the recruitments and/or activations of the dendritic cells and B cells from inguinal lymph nodes of BALB/c mice vaccinated with rLBNSE-Gn. The protective efficacy of rLBNSE-Gn against SFTSV in C57BL/6 mice was evaluated, and the virus loading in the spleens reduced to 10 TCID50/mg at 7 days post SFTSV infections, which indicated that the rLBNSE-Gn conferred efficacious protective immune responses from SFTSV in C57BL/6 mice. All the mice immunization with rLBNSE-Gn and rLBNSE survived after a lethal RABV challenge, suggesting a 100 % protection from RABV. Therefore, the rLBNSE-Gn would be a promising bivalent candidate vaccine against SFTS and rabies in animals.


Subject(s)
Antibodies, Viral/blood , Genetic Vectors , Phlebovirus/immunology , Rabies virus/genetics , Rabies/prevention & control , Severe Fever with Thrombocytopenia Syndrome/prevention & control , Viral Vaccines/immunology , Animals , Female , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Phlebovirus/genetics , Rabies Vaccines/administration & dosage , Rabies Vaccines/immunology , Rabies virus/immunology , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology , Vaccines, Combined/administration & dosage , Vaccines, Combined/genetics , Vaccines, Combined/immunology , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Viral Vaccines/administration & dosage , Viral Vaccines/genetics
4.
Glycoconj J ; 36(5): 419-428, 2019 10.
Article in English | MEDLINE | ID: mdl-31297734

ABSTRACT

Gangliosides altered during the pathological conditions and particularly in cancers. Here, we aimed to profile the gangliosides in breast cancer serum and propose potential biomarkers. LC-FTMS method was first used to identify all the ganglioside species in serum, then LC-MS/MS-MRM method was employed to quantitate the levels of gangliosides in serum from healthy volunteers and patients with benign breast tumor or breast cancer. 49 ganglioside species were determined, including GM1, GM2, GM3, GD1, GD3 and GT1 species. Compared to healthy volunteers, the levels of GM1, GM2, GM3, GD1 and GD3 displayed a rising trend in breast cancer patients. In particular, as the major glycosphingolipid component, GM3 showed excellent diagnostic accuracy in cancer serum (AUC > 0.9). PCA profile of the GM3 species showed clear distinction between normal and cancer serum. What's more, ROC curve proved great diagnostic accuracy of GM3 between cancer and benign serum. In addition, GM3 was discovered as a diagnostic marker to differentiate luminal B subtype from other subtypes. Furthermore, a positive correlation between GM3 and Ki-67 status of patients was identified. In conclusion, our results introduced the alteration patterns of serum gangliosides in breast cancer and suggested serum GM3 as a potential diagnostic biomarker in breast cancer diagnosis and luminal B subtype distinction.


Subject(s)
Biomarkers, Tumor/blood , Breast Neoplasms/diagnosis , G(M3) Ganglioside/blood , Neoplasms/diagnosis , Adult , Aged , Area Under Curve , Breast Neoplasms/blood , Breast Neoplasms/pathology , Case-Control Studies , Chromatography, Liquid , Diagnosis, Differential , Female , Gangliosides/blood , Gangliosides/classification , Humans , Ki-67 Antigen/blood , Middle Aged , Neoplasms/blood , Neoplasms/pathology , Principal Component Analysis , Prognosis , ROC Curve , Tandem Mass Spectrometry
5.
Molecules ; 24(7)2019 Apr 07.
Article in English | MEDLINE | ID: mdl-30959980

ABSTRACT

Intestinal mucins constitute the major component of the mucus covering the epithelium of the gastrointestinal tract, thereby forming a barrier against microbial colonization. Rabbits are bred in large numbers worldwide, with little known about intestinal O-glycosylation despite this insight being crucial to the understanding of host-pathogen interactions. In the present study, a major mucin-type glycopeptide (RIF6) of hyla rabbit intestine was isolated and the O-glycans were extensively characterized based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) combined with bioinformatics approaches. Thirty-three O-glycans were identified, and most of them were sulfated or sialylated glycans. It was worth noting that Neu5Gc-containing structures within sialylated O-glycans accounted for 91%, which were extremely different from that of other species including humans, mice, chickens, etc. Sulfated glycans accounted for 58%, unique disufated and sulfated-sialylated glycans were also detected in rabbit intestinal mucin. These structural characterization reflected species diversity and may provide deeper insights into explaining the adaptability of hyla rabbit to the environment.


Subject(s)
Metabolome , Metabolomics , Mucins/chemistry , Neuraminic Acids/chemistry , Polysaccharides/chemistry , Sulfates/chemistry , Animals , Chromatography, Liquid , Fucose/chemistry , Gastrointestinal Tract/metabolism , Metabolomics/methods , Mucins/isolation & purification , Mucins/metabolism , Neuraminic Acids/metabolism , Polysaccharides/metabolism , Rabbits , Structure-Activity Relationship , Tandem Mass Spectrometry
6.
Exp Cell Res ; 378(2): 171-181, 2019 05 15.
Article in English | MEDLINE | ID: mdl-30880029

ABSTRACT

Paget's disease (PD) features abnormal osteoclasts (OC) which sharply increase in number and size and then intensely induce bone resorption. The purpose of this study was to determine the direct effects of canine distemper virus (CDV) and its fusion protein and hemagglutinin protein (F + H) on receptor activator of nuclear factor kappa-B ligand (RANKL) induced OC formation in vitro. Immunofluorescence assay, OC morphological and functional detection, intracellular signaling pathway detection, Real-time PCR analysis and ELISA were applied in this study. Immunofluorescence assay provided the conclusive proof that CDV can infect and replicate in RAW264.7 mouse monocyte cell line, primary human peripheral blood mononuclear cells (PBMC) and their further fused OC. Both CDV and F + H significantly promoted OC formation and bone resorption ability induced by RANKL. Meanwhile, intracellular signaling transduction analysis revealed CDV and F + H specifically upregulated the phosphorylation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) induced by RANKL, respectively. Furthermore, without RANKL stimulation, both CDV and F + H slightly induced OC-like cells formation in RAW264.7 cell line even in the presence of NF-κB inhibitor. F + H upregulate OC differentiation and activity through modulation of NF-κB signaling pathway, and induce OC precursor cells merging dependent on the function of glycoproteins themselves. These results meant that F and H proteins play a pivotal role in CDV supporting OC formation. Moreover, this work further provide a new research direction that F and H proteins in CDV should be considered as a trigger during the pathogenesis of PD.


Subject(s)
Distemper Virus, Canine/physiology , Hemagglutinins, Viral/physiology , Osteoclasts , Viral Fusion Proteins/physiology , Animals , Cell Differentiation/genetics , Cell Fusion , Chlorocebus aethiops , Cytokines/metabolism , Humans , Mice , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Osteoclasts/virology , RANK Ligand/metabolism , RAW 264.7 Cells , Vero Cells
7.
Biochem Biophys Res Commun ; 461(1): 21-7, 2015 May 22.
Article in English | MEDLINE | ID: mdl-25849888

ABSTRACT

Paclitaxel (PTX) is commonly used in the chemotherapy of ovarian cancer, but resistance occurs in most cases, allowing cancer progression. The Wnt/ß-catenin pathway has been associated with this resistance, but there are no reports on the regulation of ß-catenin expression at the translational level. In the present study, we found that PTX induced different transcription and translation levels of ß-catenin in the human ovarian cancer cell lines A2780 and SKOV3. We also demonstrated that ß-catenin mRNA contained an internal ribosome entry segment (IRES) that regulated its translation. Using gene transfection and reporter assays, we revealed that the entire CTNNB1 5'-untranslated region (UTR) contributed to IRES activity. Interestingly, we found that c-myc and cyclin D1 increased significantly in transfected cells with increasing PTX concentration, and cell-survival rates remained at 60% while the PTX concentration increased. Suppressing ß-catenin resulted in decreased expression of c-myc and cyclin D1 and made these cells less resistant. These results indicate that ß-catenin translation is initiated via the IRES and this is regulated by PTX, suggesting that regulation of the IRES-dependent translation of ß-catenin may be involved in the cancer cell response to PTX treatment.


Subject(s)
Gene Expression Regulation, Neoplastic/drug effects , Ovarian Neoplasms/metabolism , Paclitaxel/administration & dosage , Ribosomes/metabolism , Transcriptional Activation/drug effects , beta Catenin/metabolism , Antineoplastic Agents, Phytogenic/administration & dosage , Cell Line, Tumor , Dose-Response Relationship, Drug , Female , Humans , Ovarian Neoplasms/drug therapy
8.
J Chromatogr A ; 1306: 12-9, 2013 Sep 06.
Article in English | MEDLINE | ID: mdl-23890556

ABSTRACT

Purification of four flavonoids from Rhodiola rosea was developed by on-line combination of sample preparation and counter-current chromatography (CCC). Flavonoid sample was prepared by dynamic ultrasonic-assisted and solid-phase extraction using ion liquids as extractant. The preparation conditions were optimized by D-optimal design as follows: 2mol/L of 1-ethyl-3-methylimidazolium bromide concentration, 360W of ultrasonic power, 1.5mL/min of flow rate, 35min of extraction time and 0.5mL (absorbent) per g (material) of absorbent amount. The prepared sample solution (20mL) was loaded and injected directly into CCC column for final separation. As a result, four flavonoids, herbacetin-3-O-ß-d-glucopyranosyl-7-O-α-l-rhamnopyranoside 1 (40.1mg), kaempferol-3-O-ß-d-glucopyranosyl-7-O-α-l-rhamn-opyranoside 2 (4.6mg), kaempferol 3-O-ß-d-glucopyranoside-(2→1)-ß-d-xylopyranoside 3 (20.2mg) and herbacetin-8-O-ß-d-glucopyranoside 4 (22.5mg), were obtained from 20g of R. rosea material using ethyl acetate-n-butanol-H2O as solvent system at a ratio of 4:1:5 by CCC. Their structures were identified by ESI-MS/MS, NMR methods. Their purities determined by UPLC were 98.5%, 95.4%, 98.1% and 97.5%, respectively. Kaempferol-3-O-ß-d-glucopyranosyl-7-O-α-l-rhamnopyranoside 2 and herbacetin-8-O-ß-d-glucopyrano-side 4 were isolated for first time from R. rosea. The purification method was simple, efficient and evaded tedious sample preparation process.


Subject(s)
Countercurrent Distribution/methods , Flavonoids/chemistry , Flavonoids/isolation & purification , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Rhodiola/chemistry , Solid Phase Extraction/methods , Automation , Molecular Structure
SELECTION OF CITATIONS
SEARCH DETAIL
...